donitriptan donitriptan donitriptan (inn) (code name f-11356) is a triptan drug which was investigated as an antimigraine agent but ultimately was never marketed. it acts as a high-affinity, high-efficacy/near-full agonist of the 5-ht1b (pki = 9.4–10.1; ia = 94%) and 5-ht1d receptors (pki = 9.3–10.2; ia = 97%), and is among the most potent of the triptan series of drugs. donitriptan was being developed in france by biomérieux-pierre fabre and made it to phase ii clinical trials in europe before development was discontinued. donitriptanclinical dataatc codenonelegal statuslegal status never marketed identifiers iupac name 4-oxy}acetyl)-1-piperazinyl]benzonitrile cas number170912-52-4pubchem cid197706chemspider171128unii70968bvh2jchemblchembl1742428comptox dashboard (epa)dtxsid20168974 chemical and physical dataformulac23h25n5o2molar mass403.486 g·mol−13d model (jsmol)interactive image smiles c1cc(ccc1c#n)n2ccn(cc2)c(=o)coc3ccc4c(c3)c(c4)ccn inchi inchi=1s/c23h25n5o2/c24-8-7-18-15-26-22-6-5-20(13-21(18)22)30-16-23(29)28-11-9-27(10-12-28)19-3-1-17(14-25)2-4-19/h1-6,13,15,26h,7-12,16,24h2key:sohckwzvtctqbg-uhfffaoysa-n